IRBESARTAN HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H28N6O.ClH
Molecular Weight	464.99
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NN=NN5

InChI

InChIKey=ZUYFSRQJPNUOQU-UHFFFAOYSA-N

InChI=1S/C25H28N6O.ClH/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23;/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30);1H

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf | https://www.drugs.com/cdi/irbesartan.html

Irbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It was developed by Sanofi Research (now part of Sanofi-Aventis). It is marketed under the trade names Aprovel, Karvea, and Avapro. AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Type-1 angiotensin II receptor 41 Target ID: CHEMBL227 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/10193788 \| https://www.ncbi.nlm.nih.gov/pubmed/8230127	Antagonist 2849		1.1 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 575 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020757s055lbl.pdf	Primary		Approved 8583	AVAPRO Approved Use AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria Launch Date 1997
Diabetic nephropathy 37 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf	Primary		Approved 8583	AVAPRO Approved Use AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria Launch Date 1997

C_max

Value	Dose	Analyte	Population
1.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.04 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	900 mg 1 times / day multiple, oral dose: 900 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
9.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
20 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
32.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
44.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
9.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
19.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
31.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
34.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	900 mg 1 times / day multiple, oral dose: 900 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
16 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9549663	900 mg 1 times / day multiple, oral dose: 900 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IRBESARTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
10% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020758s079lbl.pdf	unknown, unknown		IRBESARTAN serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
900 mg 1 times / day multiple, oral Highest studied dose Dose: 900 mg, 1 times / day Route: oral Route: multiple Dose: 900 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9549663	healthy, 20-45 Health Status: healthy Age Group: 20-45 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9549663	Sources: https://pubmed.ncbi.nlm.nih.gov/9549663
300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf	Disc. AE: Disorder fetal... AEs leading to discontinuation/dose reduction: Disorder fetal Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf
300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf	Disc. AE: Hyperkalemia... AEs leading to discontinuation/dose reduction: Hyperkalemia (2.1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf

AEs

AE	Significance	Dose	Population
Disorder fetal	Disc. AE	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf
Hyperkalemia	2.1% Disc. AE	300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	substrate 1193 inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A1 132 CYP1A2 2153 CYP2A6 879 CYP2B6 926 CYP2E1 1060 Kv4.3 16 P-gp 1741 BCRP 910 MRP2 499

Drug as perpetrator

Target	Modality	Activity
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: -	no [IC50 224 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: -	no [IC50 483 uM]
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: -	no [IC50 >1000 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: -	no [IC50 >1000 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: -	no [IC50 >1000 uM]
BCRP 985	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/20222053/ Page: -	no
CYP1A1 272	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020757s071lbl.pdf#page=13 Page: 13.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020757s071lbl.pdf#page=13 Page: 13.0	no
MRP2 625	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/20222053/ Page: -	no
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/20222053/ Page: -	weak
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: -	yes [IC50 172 uM]
Kv4.3 16	inhibitor 4027 Sources: https://jpet.aspetjournals.org/content/304/2/862 Page: -	yes [IC50 7.2 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020757s071lbl.pdf#page=12 Page: 12.0	yes
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020757s071lbl.pdf#page=12 Page: 12.0	yes		yes (co-administration study) Comment: in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020757s071lbl.pdf#page=12 Page: 12.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://jpet.aspetjournals.org/content/304/2/862 Page: -

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5959	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5959
ChemicalBook	CB4454663	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4454663
eMolecules	32278040	https://www.emolecules.com/cgi-bin/more?vid=32278040
eMolecules	901986	https://www.emolecules.com/cgi-bin/more?vid=901986
MolPort	MolPort-003-666-550	https://www.molport.com/shop/molecule-link/MolPort-003-666-550
MolPort	MolPort-006-167-687	https://www.molport.com/shop/molecule-link/MolPort-006-167-687
Selleck Chemicals	Irbesartan(Avapro)	http://www.selleckchem.com/products/Irbesartan(Avapro).html
ZINC	ZINC000003872931	http://zinc15.docking.org/substances/ZINC000003872931

PubMed

Title	Date	PubMed
Irbesartan slows the development of diabetic nephropathy by up to 70% in hypertensive diabetic patients.	2002-01-05	11766619
Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure.	2002-01-05	11766617
Vasoconstriction is determined by interstitial rather than circulating angiotensin II.	2002-01	11786504
Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo.	2002-01	11752132
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.	2001-12	11773985
AT(2) receptor-mediated vasodilation in the heart: effect of myocardial infarction.	2001-12	11709427
Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease.	2001-11-15	11704378
Drug companies should not have the final say in the design of clinical trials.	2001-11	11684568
Influence of irbesartan and enalapril on changes of renal function associated with the established phase of l-NAME hypertension.	2001-11	11677370
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.	2001-10-15	11700829
Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans.	2001-10-09	11591618
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.	2001-10-06	11588406
[Irbesartan in hypertension. A plus for therapy compliance].	2001-10-04	11692850
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].	2001-10-01	11601118
[Clinical study of the month. Nephroprotective role of angiotensin II receptor antagonists in type 2 diabetes: results of the IDNT and RENAAL trials].	2001-10	11765585
Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats.	2001-10	11641303
Relation between clinical and therapeutic variables and quality of life in hypertension.	2001-10	11593114
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.	2001-10	11593107
Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.	2001-10	11593101
Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.	2001-10	11593098
A clinical trial in type 2 diabetic nephropathy.	2001-10	11576953
Angiotensin II receptor blockers and nephropathy trials.	2001-10	11574450
pK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry.	2001-10	11489393
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.	2001-09-20	11565519
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.	2001-09-20	11565517
Impact of the renin-angiotensin system on cerebral perfusion following subarachnoid haemorrhage in the rat.	2001-09-01	11533142
Adenovirus-mediated overexpression and stimulation of the human angiotensin II type 2 receptor in porcine cardiac fibroblasts does not modulate proliferation, collagen I mRNA expression and ERK1/ERK2 activity, but inhibits protein tyrosine phosphatases.	2001-09	11692164
Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis.	2001-09	11592599
Differentiation in the angiotensin II receptor 1 blocker class on autonomic function.	2001-09	11580884
Angiotensin II-induced apoptosis in rat cardiomyocyte culture: a possible role of AT1 and AT2 receptors.	2001-09	11564990
The pharmacokinetics and pharmacodynamics of irbesartan in heart failure.	2001-09	11549097
Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.	2001-09	11486253
Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice.	2001-09	11486244
[Effects of inhibitors of angiotensin-converting enzyme combined with antagonists of angiotensin II receptors on endothelial function in patients with chronic cardiac insufficiency].	2001-08-25	11519426
New stuff about the diabetic kidney.	2001-08-11	11498657
[Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].	2001-08-09	11556191
Acute oliguric renal failure associated with angiotensin II receptor antagonists.	2001-08	11501548
Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension.	2001-08	11487548
Irbesartan achieves consistent and effective use over 1 year.	2001-07-28	11474701
[Angiotensin II receptor antagonists: different or equivalent?].	2001-07-27	11471284
Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension.	2001-07	11508272
Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries.	2001-04	11468024
Pharmacology of AT1-receptor blockers.	2001	11683476
The relationship between dose and antihypertensive effect for different AT1-receptor blockers.	2001	11683475
Clinical comparative trials of angiotensin II type 1 (AT1)-receptor blockers.	2001	11683472
[Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress].	2001	11642211
Drug interactions with irbesartan.	2001	11523726
[Choosing the dose of aprovel (irbesartan) in patients with chronic heart insufficiency].	2001	11521382
Hypertension and diabetes: the scope of the problem.	2001	11465914
Clinical differences among angiotensin II receptor antagonists.	2001	11465913

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Hypertension Initial dose: 150 mg orally once a day Maximum dose: 300 mg orally once a day Usual Adult Dose for Diabetic Nephropathy Target maintenance dose: 300 mg orally once a day Use: Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (greater than 300 mg/day) in patients with type 2 diabetes and hypertension.

Route of Administration: Oral

In Vitro Use Guide

0.1 uM irbesartan completely blocked the maximum response to Ang I (from 45.8 +/- 6.7% to 1.9 +/- 1.9%, p < 0.001)

Name

Type

Language

IRBESARTAN HCL

Preferred Name

English

IRBESARTAN HYDROCHLORIDE

Common Name

English

1,3-DIAZASPIRO(4.4)NON-1-EN-4-ONE, 2-BUTYL-3-((2'-(2H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

Irbesartan hydrochloride [WHO-DD]

Common Name

English

IRBESARTAN HYDROCHLORIDE [EMA EPAR]

Common Name

English

Code System Code Type Description

SMS_ID

100000090854